HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Highlights Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:09:12 05/06/2026 BST			5-day change	1st Jan Change
29.32 ^HKD	-1.61%		-6.74%	-18.74%

06-04	Hansoh Pharmaceutical's Weight-loss Injection Enters China Review	MT
05-28	Higher Crude, Persian Gulf Outlooks Lowers Asian Stock Markets	MT

Highlights

06-04	Hansoh Pharmaceutical's Weight-loss Injection Enters China Review	MT
05-13	Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval for Hs-10541 Tablets	CI
05-13	Hansoh pharmaceutical says HS-10541 tablets obtain clinical trial approval from China's NMPA	RE
05-11	The Nmpa Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093For Esophageal Squamous Cell Carcinoma	CI
05-11	Hansoh Pharmaceutical's HS-20093 Receives China Breakthrough Therapy Designation in Another Indication	MT
05-11	Hansoh pharmaceutical says NMPA grants breakthrough-therapy designation to Hansoh Pharma's HS-20093 for ESCC	RE
04-29	Hansoh Pharmaceutical Group Company Limited Announces Nmpa Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for Castration-Resistant Prostate Cancer	CI
04-29	Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approvals for HS-10522 Tablets	CI
04-16	Hansoh Pharmaceutical says NMPA grants breakthrough-therapy designation to HS-20093 with adebrelimab	RE
04-16	Hansoh Pharmaceutical Group Company Limited Announces NMPA Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 in Combination with Adebrelimab	CI
04-02	Jiangsu Hansoh Pharmaceutical Co., Ltd. Announces Third Indication Approval For XINYUE For Treatment Of Generalized Myasthenia Gravis In Adult Patients	CI
03-30	Hansoh Pharmaceutical's Profit, Revenue Climb in 2025	MT
03-29	Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	China's Hansoh Pharmaceutical Group beats net profit expectations in 2025	RE
03-29	Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend for the Year Ended December 31, 2025, Payable on July 24, 2026	CI
03-27	Hansoh pharmaceutical says Xinyue (inebilizumab injection) granted NMPA approval for new indication	RE
03-27	Hansoh Pharmaceutical Group Company Limited Receives Drug Registration Approval for Third Indication of Xinyue (Inebilizumab Injection)	CI
03-23	Hansoh Pharmaceutical Receives Chinese Regulatory Nod for Clinical Trials	MT
03-23	Hansoh Pharmaceutical says HS-20152 injection receives clinical trial approval from NMPA	RE
03-23	Hansoh Pharmaceutical gets clinical trial approval for HS-10587 tablets issued by NMPA China	RE
03-22	Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval For HS-20152 Injection	CI
03-22	Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval for HS-10587 TABLETS	CI
02-27	Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Dalmelitinib Mesylate Tablets Has Been Accepted by the National Medical Products Administration	CI
02-20	Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy	CI
02-20	Hansoh Pharmaceutical says aumolertinib mesylate tablets approved in EU as monotherapy	RE